Beltrán-Miranda C P, Khan A, Jaloma-Cruz A R, Laffan M A
Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK.
Haemophilia. 2005 Jul;11(4):326-34. doi: 10.1111/j.1365-2516.2005.01107.x.
The clinical phenotype of patients with haemophilia A (HA) often differs between individuals with the same factor VIII (FVIII) gene defect (e.g. within the same family) or the same coagulant activity of FVIII (FVIII:C). We proposed that because the thrombin generation assay in platelet-poor plasma of HA patients provides more information [peak thrombin concentration, endogenous thrombin potential (ETP), rate of thrombin generation and lag-time] than a clot-based FVIII assay it might provide insight into these differences. We therefore investigated the relation between the results of the thrombin generation assay and the clinical severity in nine families with HA (23 patients with different phenotypes). We also examined the contribution of prothrombotic risk factors: (FV Leiden G1691A and prothrombin G20210A), the coagulant activity of FVIII and tissue factor (5'UTR) polymorphisms. Our data detect marked differences between individuals but these did not correlate with the reported clinical phenotype. These differences were also reflected in a marked difference in response to the therapeutic amounts of FVIII. This might account for differences in amounts of treatment consumption. Reduced peak and possibly rate of thrombin generation, rather than FVIII:C or ETP appear to represent the critical defects in FVIII-deficient plasma. We suggest that the analysis of parameters in thrombin generation is a useful tool to detect bleeding tendency in HA but not to predict the modulation of the haemorrhagic tendency in patients within families. However the presence of the other factors such as vessel wall components, protein C and platelets might need to be incorporated into this system.
A型血友病(HA)患者的临床表型在具有相同凝血因子VIII(FVIII)基因缺陷的个体之间(例如在同一家族内)或FVIII具有相同凝血活性(FVIII:C)的个体之间往往存在差异。我们提出,由于在HA患者的乏血小板血浆中进行的凝血酶生成试验比基于凝血的FVIII试验能提供更多信息(凝血酶峰值浓度、内源性凝血酶潜力(ETP)、凝血酶生成速率和延迟时间),它可能有助于深入了解这些差异。因此,我们研究了九个HA家族(23名具有不同表型的患者)中凝血酶生成试验结果与临床严重程度之间的关系。我们还研究了血栓形成前危险因素的作用:(FV Leiden G1691A和凝血酶原G20210A)、FVIII的凝血活性以及组织因子(5'UTR)多态性。我们的数据检测到个体之间存在显著差异,但这些差异与所报道的临床表型无关。这些差异也反映在对FVIII治疗量的反应上存在显著差异。这可能解释了治疗消耗量的差异。凝血酶生成峰值降低以及可能的生成速率降低,而非FVIII:C或ETP,似乎代表了FVIII缺乏血浆中的关键缺陷。我们认为,分析凝血酶生成参数是检测HA出血倾向的有用工具,但不能预测家族内患者出血倾向的调节情况。然而,可能需要将血管壁成分、蛋白C和血小板等其他因素纳入该系统。